- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Fistulising Crohn’s disease (FCD)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Upadacitinib – March 2026
Tablet 15 mg, Tablet 30 mg, Tablet 45 mg
Last updated
11 March 2026